ADReCS

Pharmaceutical Information

Drug Name	Saxagliptin
Drug ID	BADD_D01992
Description	Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage	Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status	approved
ATC Code	A10BH03
DrugBank ID	DB06335
KEGG ID	D08996
MeSH ID	C502994
PubChem ID	11235729
TTD Drug ID	D0K9MY
NDC Product Code	50193-4212; 0310-6100; 0310-6105; 11722-078; 0310-7100; 50370-0030; 55154-6931; 0310-7105
UNII	9GB927LAJW
Synonyms	saxagliptin \| 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate \| Onglyza \| BMS 477118 \| BMS477118 \| BMS-477118

Chemical Information

Molecular Formula	C18H25N3O2
CAS Registry Number	361442-04-8
SMILES	C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Pruritus	23.03.12.001	0.001997%
Purpura	01.01.04.003; 23.06.01.004; 24.07.06.005	-	-
Rash	23.03.13.001	0.006220%		-
Renal disorder	20.01.02.002	0.000327%		-
Renal failure	20.01.03.005	0.000818%		-
Sinusitis	11.01.13.005; 22.07.03.007	-	-
Skin disorder	23.03.03.007	-	-	-
Skin exfoliation	23.03.07.003	0.000327%		-
Skin ulcer	23.07.03.003; 24.04.03.007	0.000327%
Thrombocytopenia	01.08.01.002	0.000884%		-
Tuberculosis	11.04.01.006	-	-	-
Upper respiratory tract infection	11.01.13.009; 22.07.03.011	-	-
Urinary tract infection	11.01.14.004; 20.08.02.001	-	-
Urticaria	10.01.06.001; 23.04.02.001	-	-
Vision blurred	06.02.06.007; 17.17.01.010	0.002390%
Vomiting	07.01.07.003	0.002815%
Acute coronary syndrome	02.02.02.015; 24.04.04.011	0.000327%		-
Musculoskeletal discomfort	15.03.04.001	-	-	-
Dyslipidaemia	14.08.04.015	-	-	-
Salmonella sepsis	11.02.19.002	-	-	-
Adverse event	08.06.01.010	0.001048%		-
Cardiac disorder	02.11.01.003	0.000327%		-
Infestation	11.09.01.001; 23.11.01.002	-	-	-
Malnutrition	14.03.02.004	-	-	-
Decreased appetite	08.01.09.028; 14.03.01.005	0.000982%
Erectile dysfunction	19.08.04.001; 21.03.01.007	-	-
Immunodeficiency	10.03.02.002	-	-	-
Pancreatic neoplasm	07.21.09.004; 16.13.11.005	0.000327%		-
Renal impairment	20.01.03.010	0.004321%		-
Chronic kidney disease	20.01.03.017	-	-

The 4th Page First Pre 4 5 Next Last Total 5 Pages